Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Rhea-AI Summary

Science 37, a leader in enhancing patient access to clinical trials, has reported significant success in its partnership with a biopharmaceutical company focused on infectious disease prevention research. For a Phase 3 trial involving immunocompromised patients, Science 37 utilized its proprietary Virtual Site and Patient Recruitment solutions to achieve remarkable results:

- Recruited and enrolled 129 patients across 36 states in just 8 weeks
- Averaged 65 patient enrollments per month
- Successfully randomized and treated 42% of the trial cohort
- Achieved significant geographic, socio-economic, and cultural diversity among participants

This achievement highlights Science 37's capability to meet challenging clinical trial demands while enhancing patient access and care for vulnerable populations in a fully decentralized manner.

Positive

• Enrolled 129 patients across 36 states in 8 weeks
• Averaged 65 patient enrollments per month
• Successfully randomized and treated 42% of the trial cohort
• Achieved significant geographic, socio-economic, and cultural diversity among participants
• Demonstrated ability to meet challenging clinical trial demands for vulnerable populations

Negative

• None.

Insights

Medical Research Analyst

Science 37’s recent achievement in recruiting and enrolling 42% of a Phase 3 clinical trial cohort within just 8 weeks is notable for several reasons. First, the rapid enrollment rate demonstrates the effectiveness of their Virtual Site and Patient Recruitment solutions. For investors, this indicates that Science 37's technology can expedite clinical trials, potentially accelerating time-to-market for new therapies.

The significance of enrolling a geographically and socio-economically diverse patient population cannot be understated. Diversity in clinical trials is important for ensuring that study results are applicable to the broad patient populations that will use the treatments. This also helps meet regulatory requirements and enhances the credibility of the trial outcomes.

Additionally, the focus on immunocompromised patients highlights Science 37’s capability to manage complex and sensitive patient populations. For retail investors, this suggests that the company is well-positioned to support high-demand areas within clinical research, potentially leading to more partnerships and revenue growth.

In the short term, this achievement could make Science 37 a more attractive partner for biopharmaceutical companies, driving up its market value. In the long term, continuous successful recruitment could lead to consistent revenue streams and a solid reputation in the clinical trial industry.

Financial Analyst

This recruitment milestone by Science 37 has significant financial implications. Successfully enrolling a large portion of a Phase 3 trial cohort in a short time frame enhances the company’s credibility and positions it as a go-to provider for clinical trial recruitment solutions.

From a financial perspective, rapid enrollment can lead to faster clinical trial completion, which in turn can expedite the approval and commercialization of new drugs. This could potentially translate to performance-based incentives for Science 37 and long-term contracts with biopharmaceutical companies. An increase in partnerships can also diversify and stabilize revenue streams, contributing to steady financial growth.

Moreover, the fact that Science 37's solutions are available on a standalone basis opens up additional revenue channels. This flexibility can attract a broader range of clients, from small biotech firms to large pharmaceutical companies, thereby increasing market penetration.

Investors should watch for further announcements of new partnerships or expansions in service offerings that could signal sustained growth. However, they should also be mindful of the competitive landscape and potential technological advancements by rivals.

Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed to the recruitment and enrollment of an immunocompromised patient cohort for the sponsor’s Phase 3 trial.

Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically qualified, and enrolled 129 patients across 36 states within an 8-week timeline, averaging 65 patients per month. As the top-enrolling site, Science 37 successfully randomized and treated 42% of the cohort while achieving significant geographic, socio-economic, and cultural diversity among participants.

"Depending on the rarity of the condition or sensitivities of the target patient population, some studies are inherently more difficult to recruit and enroll," said Dr. Debra Weinstein, VP of Internal Medicine and Principal Investigator at Science 37. “The complex nature of this study underscores Science 37’s ability to meet challenging clinical trial demands while enhancing patient access and care for vulnerable populations in a fully decentralized manner.”

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated patient access offering. For more information, please visit www.science37.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
PR@science37.com

FAQ

How many patients did Science 37 (SNCE) enroll in the Phase 3 trial?

Science 37 enrolled 129 patients across 36 states for the Phase 3 trial.

What was the enrollment timeline for Science 37's (SNCE) Phase 3 trial recruitment?

Science 37 completed the enrollment of 129 patients within an 8-week timeline.

What percentage of the trial cohort did Science 37 (SNCE) successfully randomize and treat?

Science 37 successfully randomized and treated 42% of the trial cohort.

What solutions did Science 37 (SNCE) use for patient recruitment in the Phase 3 trial?

Science 37 leveraged its proprietary Virtual Site and Patient Recruitment solutions for the Phase 3 trial recruitment.